Efficacy of Selective Estrogen Receptor Modulators in Nude Mice Bearing Human Transitional Cell Carcinoma

Urology

Volumn 69, Issue 6, 2007, Pages 1221-1226

  Sonpavde, Guru ^a,b   Okuno, Norihiko ^b   Weiss, Heidi ^b   Yu, Jiang ^b   Shen, Steven S ^c   Younes, Mamoun ^b   Jian, Weiguo ^b   Lerner, Seth P ^b   Smith, Carolyn L ^b  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; FULVESTRANT; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG PELLET; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA; TUMOR VOLUME; TUMOR XENOGRAFT; UROGENITAL TRACT TUMOR;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; UROGENITAL NEOPLASMS;

EID: 34249984161     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.02.041     Document Type: Article

References (30)

1. Nilsson S., Mäkelä S., Treuter E., et al. Mechanisms of estrogen action. Physiol Rev 81 (2001) 1535-1565
2. Taylor A.H., and Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol 24 (2000) 145-155
3. Salmi S., Santti R., Gustafsson J.-A., et al. Co-localization of androgen receptor with estrogen receptor beta in the lower urinary tract of the male rat. J Urol 166 (2001) 674-677
4. Makela S., Strauss L., Kuiper G., et al. Differential expression of estrogen receptors alpha and beta in adult rat accessory sex glands and lower urinary tract. Mol Cell Endocrinol 170 (2000) 219-229
5. Rosenfeld C.S., Ganjam V.K., Taylor J.A., et al. Transcription and translation of estrogen receptor-beta in the male reproductive tract of estrogen receptor-alpha knock-out and wild-type mice. Endocrinology 139 (1998) 2982-2987
6. Carley M.E., Rickard D.J., Gebhart J.B., et al. Distribution of estrogen receptors alpha and beta mRNA in mouse urogenital tissues and their expression after oophorectomy and estrogen replacement. Int Urogynecol J 14 (2003) 141-145
7. Savolainen S., Santti R., Streng T., et al. Sex specific expression of progesterone receptor in mouse lower urinary tract. Mol Cell Endocrinol 230 (2005) 17-21
8. Noronha R.F.X., and Rao B.R. Sex hormone receptors in localized and advanced transitional cell carcinoma of urinary tract in humans. Urology 28 (1986) 401-403
9. Kaufmann O., Baume H., and Dietel M. Detection of oestrogen receptors in non-invasive and invasive transitional cell carcinomas of the urinary bladder using both conventional immunohistochemistry and the tyramide staining amplification (TSA) technique. J Pathol 186 (1998) 165-168
10. Basakci A., Kirkali Z., Tuzel E., et al. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 41 (2002) 342-345
11. Shen S.S., Smith C.L., Hsieh J.T., et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 106 (2006) 2610-2616
12. Kim H.T., Kim B.C., Kim I.Y., et al. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells. J Biol Chem 277 (2002) 32510-32515
13. Witte D., Chirala M., Younes A., et al. Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Hum Pathol 32 (2001) 940-944
14. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 97 (2005) 1652-1662
15. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282 (1999) 637-645
16. Mandlekar S., and Kong A.-N.T. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6 (2001) 469-477
17. Sporn M.B., Dowsett S.A., Mershon J., et al. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clin Therapeutics 26 (2004) 830-840
18. Liu J., Albert J.D., Geller J., et al. Effect of tamoxifen on stromal protein synthesis in the human prostate. J Clin Endocrinol Metab 59 (1984) 710-713
19. Harris H.A., Bruner K.L., Zhang X., et al. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod 20 (2005) 936-941
20. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365 (2005) 1687-1717
21. Brandes A.A., Ermani M., Turazzi S., et al. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol 17 (1999) 645-650
22. Barbare J.C., Bouche O., Bonnetain F., et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23 (2005) 4338-4346
23. Hansmann A., Adolph C., Vogel T., et al. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100 (2004) 612-620
24. Lens M.B., Reiman T., and Husain A.F. Use of tamoxifen in the treatment of malignant melanoma. Cancer 98 (2003) 1355-1361
25. O'Regan R.M., Gajdos C., Dardes R.C., et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 94 (2002) 274-283
26. Kim I.Y., Seong D.H., Kim B.C., et al. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res 62 (2002) 3649-3653
27. Pu Y.S., Hsieh T.S., Tsai T.C., et al. Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J Urol 154 2 Pt 1 (1995) 601-605
28. Pu Y.S., Hsieh T.S., Cheng A.L., et al. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. Br J Urol 77 (1996) 76-85
29. Hsu C.H., Chen J., Wu C.Y., et al. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res 21 (2001) 711-715
30. Dellagrammaticas D., Bryden A.A., and Collins G.N. Regression of metastatic transitional cell carcinoma in response to tamoxifen. J Urol 165 (2001) 1631